98%
921
2 minutes
20
Objective: Accidental daily dosing of methotrexate can result in life-threatening toxicity. We investigated methotrexate dosing errors reported to the National Coronial Information System (NCIS), the Therapeutic Goods Administration Database of Adverse Event Notifications (TGA DAEN) and Australian Poisons Information Centres (PICs).
Design And Setting: A retrospective review of coronial cases in the NCIS (2000-2014), and of reports to the TGA DAEN (2004-2014) and Australian PICs (2004-2015). Cases were included if dosing errors were accidental, with evidence of daily dosing on at least 3 consecutive days.
Main Outcome Measures: Events per year, dose, consecutive days of methotrexate administration, reasons for the error, clinical features.
Results: Twenty-two deaths linked with methotrexate were identified in the NCIS, including seven cases in which erroneous daily dosing was documented. Methotrexate medication error was listed in ten cases in the DAEN, including two deaths. Australian PIC databases contained 92 cases, with a worrying increase seen during 2014-2015. Reasons for the errors included patient misunderstanding and incorrect packaging of dosette packs by pharmacists. The recorded clinical effects of daily dosage were consistent with those previously reported for methotrexate toxicity.
Conclusion: Dosing errors with methotrexate can be lethal and continue to occur despite a number of safety initiatives in the past decade. Further strategies to reduce these preventable harms need to be implemented and evaluated. Recent suggestions include further changes in packet size, mandatory weekly dosing labelling on packaging, improving education, and including alerts in prescribing and dispensing software.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5694/mja15.01242 | DOI Listing |
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Clozapine, the only drug approved by the FDA for treatment-resistant schizophrenia, operates within a narrow therapeutic range (0.35-0.60 mg/mL) and requires titration from 12.
View Article and Find Full Text PDFDermatol Surg
September 2025
Etre Cosmetic Dermatology and Laser Center, New Orleans, Louisiana.
Background: Botulinum neurotoxins in aesthetic medicine require reconstitution, which may cause administration errors.
Objective: To evaluate liquid nivobotulinumtoxinA treatment of lateral canthal lines (LCL) and glabellar lines (GL).
Materials And Methods: Participants with moderate-to-severe LCL with/without moderate-to-severe GL were enrolled in 2 double-blind randomized clinical trials.
Int J Antimicrob Agents
September 2025
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan
Objectives: The pharmacokinetics of renally cleared vancomycin are significantly altered in critically ill patients undergoing renal replacement therapy (RRT), affecting the achievement of therapeutic targets. We evaluated the predictive performance of RRT patient-based PopPK models for model-informed precision dosing and subsequently simulated optimal dosing regimens for this population.
Methods: Six adult PopPK models were systematically identified and evaluated using a dataset of 226 concentrations from 23 adult patients on RRT from two study centers.
Stat Med
September 2025
Biostatistics and Data Management, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
Typical phase 1 oncology studies identify the maximum tolerated dose as the "optimal" dose for subsequent phases. With the advancement of molecular targeted agents and immunotherapies, however, evaluating two or more doses has become increasingly critical for dose selection. Such evaluation is often done in phase 2 studies in a randomized manner.
View Article and Find Full Text PDFNeurologia (Engl Ed)
September 2025
Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain; Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain; Department of Neurology, Cruces University Hospital, Osakidetza, Barakaldo, Bizkaia, Spain.
Introduction: Differences in the trajectory of non-motor symptoms (NMS) between male and female Parkinson's disease (PD) patients over the course of the disease are not well-understood.
Methods: PD patients were rated with Non-Motor Symptom Scale (NMSS) at two time points with a median follow-up of 3.8 years (IQR 2.